Enanta Pharmaceuticals (ENTA) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enanta Pharmaceuticals (ENTA) has outperformed Immuneering (IMRX) over the past year, losing 40.1% versus a loss of 53.7%. Over five years, IMRX leads with a -85.0% price change compared with -91.7% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $218.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | IMRX |
|---|---|---|
| Share price | $7.62 | $3.38 |
| Market cap | $222.19M | $218.90M |
| 1-day change | -4.51% | -2.03% |
| YTD return | -51.68% | -48.63% |
| 1-year return | -40.14% | -53.70% |
| 5-year return | -91.71% | -85.00% |
| EPS (TTM) | $-2.35 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.00M | — |
| Revenue growth (YoY) | -3.56% | — |
| Net income (latest FY) | $-68.25M | $-56.02M |
| Operating margin | -99.01% | — |
| Net margin | -108.33% | — |
| 52-week high | $17.15 | $8.48 |
| 52-week low | $7.56 | $3.29 |
| Distance from 52-week high | -55.57% | -60.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +186.48% | +402.96% |
| Average volume | 287.81K | 747.66K |
| Shares outstanding | 29.16M | 64.76M |
| Employees | 120 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTA has outperformed IMRX by 13.6 percentage points over the past year.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ENTA vs IMRX FAQ
Which is bigger, Enanta Pharmaceuticals or Immuneering?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $218.90M for Immuneering (IMRX).
Which stock has performed better over the past year, ENTA or IMRX?
ENTA returned -40.14% over the past 12 months, compared with -53.70% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Immuneering in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.